Updated Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer
- March 22, 2019
- Administrative, Clinical Practice Updates, Drugs, News
National Comprehensive Cancer Network© (NCCN©) has updated the Clinical Practice Guidelines in Oncology for Colon and Rectal Cancer to include BRAFTOVI® in combination with MEKTOVI® and cetuximab or panitumumab as a Category 2a treatment for patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), after failure of one to two prior lines of therapy for metastatic disease. This recommendation, as well FDA Breakthrough Therapy Designation, was based on the strength of data from the BEACON CRC safety lead-in, which was shared most recently at the ASCO 2019 Gastrointestinal Cancers Symposium in January.
Source: Array Biopharma
